MA-KANGURU
5.12.2019 17:33:11 CET | Business Wire | Press release
Kanguru is proud to announce the launch of the world’s first OS Agnostic, Fingerprint Access Hardware Encrypted Flash Drive with remote management capability. This new biometric fingerprint access flash drive supplants the bulky pinpads and fussy combo keypads of leading encrypted devices, making it much more convenient and easy to use. With just a tap of the finger, the new Kanguru Defender Bio-Elite30™ Fingerprint Hardware Encrypted Flash Drive provides quick access to encrypted files.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005662/en/
Being OS Agnostic, the Defender Bio-Elite30 can be used on virtually any machine, from Windows and MacOS, to medical equipment, smart TVs and even ATMs for making bank machine updates. This makes it highly versatile for all types of industries.
With best-in-class AES 256-Bit hardware encryption, the new biometric fingerprint encrypted flash drive allows a user to assign multiple finger access for themselves, and/or others whom they authorize. Permissions can be enabled for full read/write secure entry, or read only restricted access to allow users to simply view the encrypted files.
The Defender Bio-Elite30 Fingerprint secure flash drive is USB powered, rising above all other competitive devices that require a battery which could fail at the worst possible time.
“The Defender Bio-Elite30 fingerprint encrypted flash drive has tremendous value for any type of environment,” states Nate Cote, Executive VP of Kanguru, “It’s convenient, secure, and versatile.”
The exceptional features of the Defender Bio-Elite30 Fingerprint Encrypted Flash Drive rival any similar device on the market:
- OS Platform Agnostic (Use On Virtually Any Machine)
- Full 256-Bit Hardware Encryption (XTS Mode)
- Assign Multi-Finger Access For Each Fingerprint or User(s)
- Features New Command Console With Onboard Browser
- Option To Remotely Manage With Kanguru Remote Management Console (KRMC™)
- Optional On-board AntiVirus, Real-Time Scanning Protection by Award Winning BitDefender ®
- RSA-2048 Digitally-Signed Secure Firmware
- TAA Compliant
To learn more about the new Kanguru Defender Bio-Elite30 Fingerprint Hardware Encrypted Flash Drive , please visit kanguru.com or call 1-888-KANGURU .
Kanguru Solutions is a global leader in manufacturing high-quality secure data storage products, fully-integrated remote management, duplication equipment and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191205005662/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom